Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Administration, Metronomic
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cell Line, Tumor
Cell Survival
/ drug effects
Dasatinib
/ administration & dosage
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Drug Synergism
Humans
Indoles
/ administration & dosage
Inhibitory Concentration 50
Irinotecan
/ administration & dosage
Naphthyridines
/ administration & dosage
Neuroblastoma
/ drug therapy
Purines
/ administration & dosage
Pyrimidines
/ administration & dosage
Signal Transduction
/ drug effects
Sirolimus
/ administration & dosage
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Temozolomide
/ administration & dosage
Thiourea
/ administration & dosage
ATP competitive mTOR inhibitors
Rapamycin
Torin-2
combination therapy
mTOR inhibitor
neuroblastoma
Journal
International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
05
2020
accepted:
16
10
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
7
9
2021
Statut:
epublish
Résumé
The prognosis for patients with relapsed or refractory high-risk neuroblastoma remains dismal and novel therapeutic options are urgently needed. The RIST treatment protocol has a multimodal metronomic therapy design combining molecular-targeted drugs (Rapamycin and Dasatinib) with chemotherapy backbone (Irinotecan and Temozolomide), which is currently verified in a phase II clinical trial (NCT01467986). With the availability of novel and more potent ATP competitive mTOR inhibitors, we expect to improve the RIST combination therapy. By comparing the IC
Identifiants
pubmed: 33390782
doi: 10.7150/ijms.48393
pii: ijmsv18p0137
pmc: PMC7738968
doi:
Substances chimiques
1-(4-(4-(1-cyclopropylsulfonylcyclopropyl)-6-(3-methylmorpholin-4-yl)pyrimidin-2-yl)phenyl)-3-(2-hydroxyethyl)thiourea
0
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one
0
9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one
0
Indoles
0
Naphthyridines
0
Purines
0
Pyrimidines
0
Irinotecan
7673326042
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Thiourea
GYV9AM2QAG
PP242
H5669VNZ7V
Dasatinib
RBZ1571X5H
Sirolimus
W36ZG6FT64
Temozolomide
YF1K15M17Y
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-149Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Ann Hematol. 2013 Oct;92(10):1345-50
pubmed: 23625298
Science. 1984 Jun 8;224(4653):1121-4
pubmed: 6719137
Nat Rev Cancer. 2009 Aug;9(8):550-62
pubmed: 19629070
Cancer Res. 2007 Jan 15;67(2):735-45
pubmed: 17234785
Int J Cancer. 2011 Dec 15;129(12):2958-65
pubmed: 21717457
Front Oncol. 2017 Mar 31;7:51
pubmed: 28409123
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
EMBO J. 1996 Dec 2;15(23):6541-51
pubmed: 8978681
J Biol Chem. 2009 Mar 20;284(12):8023-32
pubmed: 19150980
Oncotarget. 2016 Nov 18;8(32):52193-52210
pubmed: 28881723
Oncogene. 2008 May 1;27(20):2910-22
pubmed: 18026138
Cancer Cell. 2009 Jan 6;15(1):67-78
pubmed: 19111882
Cancer Res. 2013 Apr 15;73(8):2574-86
pubmed: 23436801
Sci Transl Med. 2012 Jan 4;4(115):115ra3
pubmed: 22218692
Semin Cell Dev Biol. 2014 Dec;36:79-90
pubmed: 25242279
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Cancer Cell. 2012 Jul 10;22(1):117-30
pubmed: 22789543
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Oncotarget. 2016 Aug 23;7(34):55690-55703
pubmed: 27494886
PLoS Biol. 2009 Feb 10;7(2):e38
pubmed: 19209957
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
pubmed: 16341064
Transplant Proc. 2003 May;35(3 Suppl):7S-14S
pubmed: 12742462
J Pediatr Hematol Oncol. 2015 May;37(4):245-51
pubmed: 25811750
Oncogene. 2007 Mar 22;26(13):1932-40
pubmed: 17001314
Lancet Oncol. 2003 Aug;4(8):472-80
pubmed: 12901961
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Oncogene. 2010 Jul 1;29(26):3733-44
pubmed: 20418915
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
J Immunol Res. 2018 Jul 11;2018:7394268
pubmed: 30116755
Front Oncol. 2015 May 12;5:111
pubmed: 26029667
Oncotarget. 2016 Sep 6;7(36):57525-57544
pubmed: 27438153
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Autophagy. 2009 Jul;5(5):725-6
pubmed: 19395872
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Clin Cancer Res. 2013 Nov 1;19(21):5814-21
pubmed: 23965898
Cancer Res. 2006 Aug 15;66(16):8139-46
pubmed: 16912192
Nat Rev Cancer. 2010 Jan;10(1):51-7
pubmed: 20029423
Cancer Discov. 2011 Aug;1(3):248-59
pubmed: 22140653
Mol Cell. 2002 Sep;10(3):457-68
pubmed: 12408816
Methods Mol Biol. 2011;731:421-34
pubmed: 21516426
Autophagy. 2007 Nov-Dec;3(6):542-5
pubmed: 17611390
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9
pubmed: 18955708
Cancer Res. 2006 Feb 1;66(3):1500-8
pubmed: 16452206
Cancer Cell. 2014 Sep 8;26(3):414-427
pubmed: 25175806
Cancer Res. 2015 Nov 1;75(21):4617-28
pubmed: 26432405
Nat Rev Cancer. 2006 Sep;6(9):729-34
pubmed: 16915295
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
Int J Cancer. 2015 Feb 15;136(4):E173-87
pubmed: 25123598
J Clin Invest. 2015 Jan;125(1):25-32
pubmed: 25654547
F1000Res. 2016 Aug 25;5:
pubmed: 27635236
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Prog Mol Subcell Biol. 1998;20:43-71
pubmed: 9928526
Mol Cell. 2006 Apr 21;22(2):159-68
pubmed: 16603397
Cancers (Basel). 2018 Jan 03;10(1):
pubmed: 29301334
J Med Chem. 2011 Mar 10;54(5):1473-80
pubmed: 21322566
Sci Data. 2017 Mar 28;4:170033
pubmed: 28350380
Children (Basel). 2018 Oct 31;5(11):
pubmed: 30384486
Dev Biol. 2015 Nov 15;407(2):344-55
pubmed: 25863122
Pol J Pathol. 2010;61(4):192-8
pubmed: 21290341
Radiographics. 2018 Mar-Apr;38(2):566-580
pubmed: 29528815
Science. 2010 May 28;328(5982):1172-6
pubmed: 20508131
Oncogene. 1999 Aug 26;18(34):4808-18
pubmed: 10490814